McNicoll, Lewis & Vlak Reiterates Rockwell Medical Buy, $16.50 PT

McNicoll, Lewis & Vlak reiterated its Rockwell Medical RMTI Buy rating and $16.50 price target in a research report published today. In the report, McNicoll, Lewis & Vlak states, "RMTI recently purchased an ANDA for generic injectable Vitamin-D known as Calcitriol. RMTI expects to complete the drug manufacturing for the ANDA in approximately 8-10 months. Since the FDA has approved the ANDA, the company expects to launch the product and begin generating sales after drug manufacturing is complete." Shares of Rockwell Medical were trading at $8.98 at the time of posting, up 2.05% from Thursday's market close.